Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00529750 |
Primary:
Secondary:
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: IRBESARTAN |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Comparative Trial of the Effects of Irbesartan vs Atenolol on the Endothelial Function of Hypertensive Patients With Metabolic Syndrome |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
With at least two of the following criteria for the diagnosis of metabolic syndrome:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study ID Numbers: | L_8261 |
Study First Received: | September 12, 2007 |
Last Updated: | March 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00529750 |
Health Authority: | Columbia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos |
Irbesartan Vascular Diseases Angiotensin II Atenolol Hypertension |
Angiotensin II Type 1 Receptor Blockers Molecular Mechanisms of Pharmacological Action Therapeutic Uses Cardiovascular Diseases |
Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |